| First-in-human Trial of PhOx430, a First-in-class Acetylglucosaminyltransferase V Inhibitor, in Advanced Solid Tumours (NCT05495295) | Phost'In Therapeutics | 2022-07-18 |
| Balancing Method for Pain Related to Advanced Cancer (NCT04176575) | University of Pittsburgh | 2022-07-05 |
| Implementing Precision Medicine in cOmmunity HospiTALs (NCT05283044) | Gustave Roussy, Cancer Campus, Grand Paris | 2022-06-29 |
| Comprehensive Outcomes for After Cancer Health (NCT05349227) | Pack Health | 2022-06-23 |
| Towards an Early Integration of Palliative Care in Oncology (NCT05339945) | Assistance Publique - Hôpitaux de Paris | 2022-06-02 |
| Actinium 225 Labeled Anti-CEA Antibody (Ac225-DOTA-M5A) for the Treatment of CEA Producing Advanced or Metastatic Cancers (NCT05204147) | City of Hope Medical Center | 2022-06-02 |
| Assessment of Sarcopenia at Diagnosis for Patients With Previously Untreated Metastatic Cancer or Hematologic Malignancy (NCT05154474) | Weprom | 2022-06-01 |
| A Study of DS-9606a in Patients With Advanced Solid Tumors (NCT05394675) | Daiichi Sankyo | 2022-05-31 |
| Parental Support Intervention in an Advanced Oncological Context (NCT07341815) | Université Libre de Bruxelles | 2022-05-27 |
| Study Comparing Standard of Care Chemotherapy With/ Without Sequential Cytoreductive Surgery for Patients With Metastatic Foregut Cancer and Undetectable Circulating Tumor-Deoxyribose Nucleic Acid Levels (NCT04931420) | University of Chicago | 2022-05-19 |
| A Study of CF33-hNIS (VAXINIA), an Oncolytic Virus, as Monotherapy or in Combination With Pembrolizumab in Adults With Metastatic or Advanced Solid Tumors (NCT05346484) | Imugene Limited | 2022-05-17 |
| Patients Characteristics, Treatment Pattern & Outcomes of Patients With Advanced, Recurrent or Metastatic Endometrial Carcinoma (NCT05364905) | ARCAGY/ GINECO GROUP | 2022-05-09 |
| MEM-288 Oncolytic Virus Alone and in Combination With Standard of Care Therapy in Advanced Solid Tumors (NCT05076760) | Memgen, Inc. | 2022-04-21 |
| Metastasis-directed Therapy for Oligorecurrent Prostate Cancer (NCT05352178) | Universitaire Ziekenhuizen KU Leuven | 2022-04-20 |
| Trial of Written Exposure for Metastatic Cancer Patients (EASE) (NCT06042400) | University of Colorado, Boulder | 2022-04-18 |
| (Peak) A Phase 3 Randomized Trial of CGT9486+Sunitinib vs. Sunitinib in Subjects With Gastrointestinal Stromal Tumors (NCT05208047) | Cogent Biosciences, Inc. | 2022-04-14 |
| Study of NG-350A Plus Pembrolizumab in Metastatic or Advanced Epithelial Tumours (FORTIFY) (NCT05165433) | Akamis Bio | 2022-04-13 |
| Niraparib in Tumors Metastatic to the CNS (NCT04992013) | Massachusetts General Hospital | 2022-04-05 |
| Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer (NCT05267626) | Aulos Bioscience, Inc. | 2022-04-04 |
| Anti-NY-ESO-1 TCR-Gene Engineered Lymphocytes Given by Infusion to Patients With NY-ESO-1 -Expressing Metastatic Cancers (NCT05296564) | Hadassah Medical Organization | 2022-04-01 |
| Niraparib in the Treatment of Patients With Advanced PALB2 Mutated Tumors (NCT05169437) | Tempus AI | 2022-03-15 |
| Ubuntu - I Am Because We Are (NCT05314179) | University of Pittsburgh | 2022-03-13 |
| Advance Care Planning in the Emergency Department (NCT05209880) | Brigham and Women's Hospital | 2022-03-01 |
| A Study of HMBD-002, a Monoclonal Antibody Targeting VISTA, as Monotherapy and Combined With Pembrolizumab, in Patients With Advanced Solid Tumors (NCT05082610) | Hummingbird Bioscience | 2022-02-28 |
| Phase 2 Basket Trial of Nab-sirolimus in Patients With Malignant Solid Tumors With Pathogenic Alterations in TSC1/TSC2 Genes (PRECISION 1) (NCT05103358) | Aadi Bioscience, Inc. | 2022-02-15 |
| Penpulimab in Combination With Cetuximab as First-line Treatment in R/M SCCHN (NCT05260671) | Eye & ENT Hospital of Fudan University | 2022-01-25 |
| A Phase 1 First-In-Human Study of the Anti-CD73 IPH5301 Alone or in Combination With Chemotherapy and Trastuzumab in Patients With Advanced Solid Tumors (NCT05143970) | Institut Paoli-Calmettes | 2022-01-21 |
| Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy Trial of BNT141 in Patients With Unresectable or Metastatic CLDN18.2-positive Gastric, Pancreatic, Ovarian and Biliary Tract Tumors (NCT04683939) | BioNTech SE | 2022-01-18 |
| Holmium-166 Retrospective Collection of Real-World Data (NCT05111795) | Terumo Europe N.V. | 2022-01-17 |
| Metastatic Pathologic Fractures, Short Term Results (NCT05825456) | Ankara University | 2022-01-01 |
| LS301 Uptake in Tumors of Patients Undergoing Liver, Pancreas, or Gastric Surgery (NCT04105062) | Washington University School of Medicine | 2021-12-31 |
| Study of NG-641 in Combination With Nivolumab in Metastatic or Advanced Epithelial Tumours (NCT05043714) | Akamis Bio | 2021-12-01 |
| Effect of Low-dose 500 mg Abiraterone Acetate in Treatment of Metastatic Prostate Cancer Patients (NCT06193993) | National University Hospital, Singapore | 2021-11-30 |
| Evaluation of Efficacy of Comprehensive Genomic Tumour Profiling (CGP) From Liquid and/or Tissue Biopsy in Patients With Locally Advanced and/or Metastatic Solid Cancer (NCT05032092) | Medical University of Graz | 2021-11-24 |
| An Expanded Clinical Study of Triple Therapy for Refractory Solid Tumors That Failed First-line Treatment for Recurrence and Metastasis (NCT05438342) | Shanghai Pudong Hospital | 2021-11-01 |
| OPTIMIzation of Treatment SElection and Follow up in Oligometastatic Colorectal Cancer (NCT04680260) | Karen-Lise Garm Spindler | 2021-10-25 |
| Maintenance Niraparib and Dostarlimab in Advanced Cholangiocarcinoma (NCT04895046) | Walid Shaib, MD | 2021-10-11 |
| Onapristone and Fulvestrant for ER+ HER2- Metastatic Breast Cancer After Endocrine Therapy and CDK4/6 Inhibitors (The SMILE Study) (NCT04738292) | University of Wisconsin, Madison | 2021-10-05 |
| Cholesterol Disruption in Combination With the Standard of Care in Patients With Advanced Pancreatic Adenocarcinoma (NCT04862260) | CHU de Quebec-Universite Laval | 2021-10-04 |
| Stereotactic Ablative Radiotherapy for Oligo-Progressive Disease REfractory to Systemic Therapy in Metastatic Cancer (NCT04989725) | Centre hospitalier de l'Université de Montréal (CHUM) | 2021-10-01 |
| A Phase II Study of Futibatinib and Pembrolizumab in Metastatic Microsatellite Stable Endometrial Carcinoma (NCT05036681) | M.D. Anderson Cancer Center | 2021-09-30 |
| 9-ING-41 Plus Carboplatin in Salivary Gland Carcinoma (NCT05010629) | Glenn J. Hanna | 2021-09-17 |
| A Study of ART4215 for the Treatment of Advanced or Metastatic Solid Tumors (NCT04991480) | Artios Pharma Ltd | 2021-09-13 |
| A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents (NCT05094804) | OncoResponse, Inc. | 2021-09-09 |
| A Phase 1，Open-label Study of BPI-421286 in Subjects With Advanced Solid Tumors (NCT05315180) | Betta Pharmaceuticals Co., Ltd. | 2021-08-24 |
| Dose Efficiency of Modern CT Scanners in Oncologic Scans (NCT04989192) | University Hospital Augsburg | 2021-08-17 |
| A Study of Reduced-dose Radiation in People With Metastatic Tumors With a Genetic Change (NCT05010031) | Memorial Sloan Kettering Cancer Center | 2021-08-11 |
| Adagrasib in Combination With BI 1701963 in Patients With Cancer (KRYSTAL 14) (NCT04975256) | Mirati Therapeutics Inc. | 2021-07-28 |
| ISPY-P1.01:Evaluating the Safety of Weekly Paclitaxel With Trastuzumab Duocarmazine (SYD985) in Patients With Metastatic Cancer (NCT04602117) | QuantumLeap Healthcare Collaborative | 2021-07-28 |
| Study of Cabozantinib Plus TAS102 in mCRC as Salvage Therapy (NCT04868773) | University of California, Irvine | 2021-07-16 |
| A Study of Stereotactic Body Radiotherapy (SBRT) and Surgical Stabilization for People With Cancer That Has Spread to the Bone (NCT05038124) | Memorial Sloan Kettering Cancer Center | 2021-06-30 |
| Study of TJ033721 (Givastomig) in Subjects With Advanced or Metastatic Solid Tumors (NCT04900818) | I-Mab Biopharma US Limited | 2021-06-29 |
| Second-line Cabozantinib and Atezolizumab in Patients With Recurrent or Metastatic Esophageal Squamous Cell Carcinoma (NCT05007613) | National Taiwan University Hospital | 2021-06-23 |
| Neratinib and Trastuzumab Biosimilar in Patients with HER2 Mutated Advanced Solid Cancers (NCT06083662) | Korea University Guro Hospital | 2021-06-15 |
| Feasibility of Supportive Care Needs in Patients With Advanced Solid Cancer in a Therapeutic Trial (NCT04896099) | Institut Curie | 2021-06-07 |
| A Study to Examine the Clinical Value of Comprehensive Genomic Profiling Performed by Belgian NGS Laboratories: a Belgian Precision Study of the BSMO in Collaboration With the Cancer Centre (NCT05058937) | The Belgian Society of Medical Oncology | 2021-06-01 |
| A Phase 2 Trial for Patients With Metastatic Solid Cancer (NCT04713371) | Rampart Health, L.L.C. | 2021-05-19 |
| Ultrasound-guided Tru-Cut Biopsy in Pelvic Masses. (NCT05610501) | Universitaire Ziekenhuizen KU Leuven | 2021-05-01 |
| Cetuximab Sensitivity Correlation Between Patient-Derived Organoids and Clinical Response in Colon Cancer Patients. (NCT04906733) | D1 Medical Technology (Shanghai) Co., Ltd, China | 2021-04-15 |
| A Study of MPT-0118 in Subjects With Advanced or Metastatic Refractory Solid Tumors (NCT04859777) | Monopteros Therapeutics Inc. | 2021-04-13 |
| OSE2101+FOLFIRI, or FOLFIRI Maintenance After FOLFIRINOX-based Induction Therapy in Advanced or Metastatic PDAC (NCT03806309) | GERCOR - Multidisciplinary Oncology Cooperative Group | 2021-04-10 |
| Circulating Tumor DNA as Marker for Response to Antineoplastic Treatment of Metastatic Cancer (FLUIDO) (NCT04793061) | Elisabethinen Hospital | 2021-04-01 |
| Interest of the Addition of Docetaxel to Standard Treatment in First-line Advanced HER2 Positive Gastroesophageal Adenocarcinoma in Selective Patients (NCT04920747) | Centre Hospitalier Universitaire de Besancon | 2021-04-01 |
| Augsburg Longitudinal Plasma Study for the Evaluation of Liquid Biopsy as Diagnostic Tool. (NCT05245136) | University Hospital Augsburg | 2021-03-29 |
| Metastatic Solid Cancer Clinical Trial (NCT04739618) | ImmunSYS, LLC | 2021-03-04 |
| Image-guided Targeted Doxorubicin Delivery With Hyperthermia to Optimize Loco-regional Control in Breast Cancer (NCT03749850) | UMC Utrecht | 2021-03-01 |
| The P10s-PADRE Basket Trial: Vaccination of Metastatic Cancer Patients (NCT03003195) | University of Arkansas | 2021-03-01 |
| Safety and Preliminary Efficacy of SNK01 in Combination With Trastuzumab or Cetuximab in Subjects With Advanced HER2 or EGFR Cancers (NCT04464967) | NKGen Biotech, Inc. | 2021-03-01 |
| A Clinical Trial Assessing BT-001 Alone and in Combination With Pembrolizumab in Metastatic or Advanced Solid Tumors (NCT04725331) | Transgene | 2021-02-25 |
| A Retro-/Prospective, Non-interventional, Cohort Study in Adult Patients With Locally Advanced or Metastatic Tumors With a Neurotrophic Tyrosine Receptor Kinase (NTRK) Gene Fusion, Treated With Larotrectinib (NCT04814667) | Centre Leon Berard | 2021-02-23 |
| Stereotactic Body Radiotherapy With or Without Darolutamide for OligoRecurrent Prostate Cancer (NCT04641078) | University Hospital, Ghent | 2021-02-12 |
| Prediction of Drug Response Using an Ex Vivo Organ Culture (EVOC) on Fresh Human Tumour Samples From Metastatic Patients (NCT04599608) | Imperial College London | 2021-02-01 |
| A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors (NCT04657068) | Artios Pharma Ltd | 2021-01-27 |
| Randomized Clinical Trial of a Multi-Modal Palliative Care Intervention (NCT04773639) | University of Colorado, Boulder | 2021-01-11 |
| Study of TJ210001 Administered in Subjects With Relapsed or Refractory Advanced Solid Tumors (NCT04678921) | I-Mab Biopharma US Limited | 2020-12-17 |
| LYT-200 Alone and in Combination With Chemotherapy or Tislelizumab in Patients With Locally Advanced or Metastatic Solid Tumors (NCT04666688) | PureTech | 2020-12-15 |
| Imaging of Solid Tumors Using FAP-2286 (NCT04621435) | Thomas Hope | 2020-12-14 |
| FS222 First in Human Study in Patients With Advanced Malignancies (NCT04740424) | invoX Pharma Limited | 2020-12-14 |
| Sym024 Monotherapy and in Combination With Sym021 in Patients With Advanced Solid Tumor Malignancies (NCT04672434) | Symphogen A/S | 2020-11-19 |
| Advanced Lung Tumor Treated by Osimertinib Plus Anlotinib (NCT04770688) | Shanghai Chest Hospital | 2020-11-19 |
| FS120 Phase 1/1b Study in Patients With Advanced Malignancies (NCT04648202) | invoX Pharma Limited | 2020-11-18 |
| Oral Axl/Mer/CSF1R Selective Tyrosine Kinase Inhibitor in Patients With Advanced Solid Tumor (NCT04648254) | Qurient Co., Ltd. | 2020-11-18 |
| ARREST - A Phase I Study of SABR for Poly-metastatic Disease (NCT04530513) | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's | 2020-11-17 |
| The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (NCT04585750) | PMV Pharmaceuticals, Inc | 2020-10-29 |
| Trial-specific Patient Decision Aid (tPDA) of the ImmunoSABR Phase 2 (NCT04604470) | Maastricht University | 2020-10-20 |
| Study of Circulating Tumor DNA (ctDNA) Kinetics in Immuno-oncology (IO-KIN) (NCT04606940) | University Health Network, Toronto | 2020-10-19 |
| Regorafenib in Combination With Metronomic Chemotherapies, and Low-dose Aspirin in Metastatic Colorectal Cancer (NCT04534218) | Centre Hospitalier Universitaire de Besancon | 2020-10-16 |
| Sym021 in Combination With Either Sym022 or Sym023 or Sym023 and Irinotecan in Patients With Recurrent Advanced Selected Solid Tumor Malignancies (NCT04641871) | Symphogen A/S | 2020-10-12 |
| A Study to Examine the Value of Broad Agnostic Next Generation Sequencing (NGS) Panel Testing Versus Reimbursed Organ-directed NGS: a Belgian Precision Study of the BSMO in Collaboration With the Cancer Center (NCT04641676) | The Belgian Society of Medical Oncology | 2020-10-09 |
| Combined Deep Inspiration Breath Hold (DIBH)-Expiration Planning Technique in Patients With Lung Tumors in Close Proximity to the Chest Wall (NCT04507828) | Indiana University | 2020-10-02 |
| A Study to Evaluate the Safety and Pharmacokinetics of OC-001 in Patients With Locally Advanced or Metastatic Cancers (NCT04260802) | Ocellaris Pharma, Inc. | 2020-09-24 |
| Immune Resistance Interrogation Study (NCT04243720) | University Health Network, Toronto | 2020-08-26 |
| Study of GNX102 in Patients With Advanced Solid Tumors (NCT04250597) | GlycoNex, Inc. | 2020-07-29 |
| Optimizing Y90 Therapy for Radiation Lobectomy (NCT04390724) | Northwestern University | 2020-07-17 |
| Comparing Dosing Intervals of Nivolumab or Pembrolizumab in Locally Advanced or Metastatic Cancers (NCT04295863) | University of Chicago | 2020-06-25 |
| Durvalumab (MEDI4736) Plus Cediranib in Patients With Metastatic Uveal Melanoma (NCT04184518) | Grupo Español Multidisciplinar de Melanoma | 2020-05-01 |
| Molecularly Targeted Umbrella Study in Luminal Advanced Breast Cancer (NCT04355858) | Fudan University | 2020-05-01 |
| Immunotherapy for the Treatment of Advanced Solid Tumor (NCT03658785) | Tongji Hospital | 2020-04-28 |
| Adagrasib in Combination With TNO155 in Patients With Cancer (KRYSTAL 2) (NCT04330664) | Mirati Therapeutics Inc. | 2020-04-07 |
| Bintrafusp Alfa in Previously Treated Patients With R/M Non-keratinizing NPC (NCT04396886) | The University of Hong Kong | 2020-02-27 |